Veripath Q4 2023 Investor Letter

Veripath Q4 2023 Investor Letter

Canadian farmland and stagflation, Canadian trends in fertilizer use View full report
Read more...
Is Canadian Growth Dead?

Is Canadian Growth Dead?

Preparing for stagflation and the “socioeconomic barbell” View full report
Read more...
Veripath Q4 2023 Fund Factsheet

Veripath Q4 2023 Fund Factsheet

Veripath R & UR Funds Q4 2023 – NAVs, fund metrics View full report
Read more...
Veripath Q3 2023 Fund Factsheet

Veripath Q3 2023 Fund Factsheet

Veripath R & UR Funds Q3 2023 – NAVs, fund metrics View full report
Read more...
Veripath Q3 2023 – Investor Letter

Veripath Q3 2023 – Investor Letter

Veripath continues to generate compelling risk-adjusted returns and a recent $60M acquisition of irrigated land in Alberta brings total assets under management (AUM) to over $350M
Read more...
Corpus, Averine & Preceptos Partners Q2 2023 Investor Updates

Corpus, Averine & Preceptos Partners Q2 2023 Investor Updates

We are pleased to present the report to unitholders for the quarter ended June 30, 2023.
Read more...
Veripath Q2 2023 – Investor Letter

Veripath Q2 2023 – Investor Letter

Veripath’s investors have confidence that our non-operated farmland thesis rests on a foundation of well researched elements.
Read more...
Q1 2023 Portfolio Operating Partnership Strategy Update

Q1 2023 Portfolio Operating Partnership Strategy Update

Update on the portfolio operating partneship strategy - Averine (royalties), Corpus (healthcare) and Preceptos (light industrial).
Read more...
Veripath Q1 2023 Fund Factsheet

Veripath Q1 2023 Fund Factsheet

Veripath Fact Sheet Q4 2022 – Check the complete report below View full report
Read more...
1 2 3 4 5 6 15